We value your privacy We use cookies to enhance your browsing experience, serve personalised ads or content, and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Customise Reject All Accept All Powered by Customise…

We value your privacy
We use cookies to enhance your browsing experience, serve personalised ads or content, and analyse our traffic. By clicking "Accept All", you consent to our use of cookies.
Customise Reject All Accept All
Powered by
Customise Consent Preferences 
We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorised as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... Show more
NecessaryAlways Active
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
-
Cookie
cookieyes-*
-
Duration
1 year
-
Description
CookieYes sets this cookie for consent solution management.
-
Cookie
AWSALBCORS
-
Duration
7 days
-
Description
Amazon Web Services set this cookie for load balancing.
-
Cookie
__cf_bm
-
Duration
1 hour
-
Description
This cookie, set by Cloudflare, is used to support Cloudflare Bot Management.
-
Cookie
ASPSESSIONID*
-
Duration
session
-
Description
Classic ASP application sets this cookie to maintain a user's session state across multiple HTTP requests. It helps the server identify and track a user's session, allowing information stored on the server to persist between pages.
-
Cookie
rc::a
-
Duration
Never Expires
-
Description
This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.
-
Cookie
rc::c
-
Duration
session
-
Description
This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.
-
Cookie
VISITOR_PRIVACY_METADATA
-
Duration
6 months
-
Description
YouTube sets this cookie to store the user's cookie consent state for the current domain.
Functional
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
-
Cookie
VISITOR_INFO1_LIVE
-
Duration
6 months
-
Description
A cookie set by YouTube to measure bandwidth that determines whether the user gets the new or old player interface.
-
Cookie
ytidb::LAST_RESULT_ENTRY_KEY
-
Duration
Never Expires
-
Description
The cookie ytidb::LAST_RESULT_ENTRY_KEY is used by YouTube to store the last search result entry that was clicked by the user. This information is used to improve the user experience by providing more relevant search results in the future.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance
Performance cookies are used to understand and analyse the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement
Advertisement cookies are used to provide visitors with customised advertisements based on the pages you visited previously and to analyse the effectiveness of the ad campaigns.
-
Cookie
__Secure-YNID
-
Duration
6 months
-
Description
YouTube cookie used to protect user security and prevent fraud, especially during the login process.
-
Cookie
__Secure-ROLLOUT_TOKEN
-
Duration
6 months
-
Description
YouTube sets this cookie to manage feature rollout and experimentation. It helps Google control which new features or interface changes are shown to users as part of testing and staged rollouts, ensuring consistent experience for a given user during an experiment.
-
Cookie
__Secure-YEC
-
Duration
past
-
Description
Description is currently not available.
Uncategorised
Other uncategorised cookies are those that are being analysed and have not been classified into a category as yet.
-
Cookie
internal_navigation_count
-
Duration
1 day
-
Description
No description available.
-
Cookie
external_referrer_url
-
Duration
1 day
-
Description
No description available.
-
Cookie
SF_PHPSESSID
-
Duration
session
-
Description
Description is currently not available.
Reject All Save My Preferences Accept All
Powered by
Skip to main content
Skip to Investors Navigation
Newsroom
Scientific Publications
Our Theranostic technology and approach has been featured in the following publications
2016-present
2026
Graves SA, Bushnell DL, Schultz MK, Jain S, Bodeker KL, Menda Y. A Phase 0 Imaging Trial of [203Pb]Pb-VMT-α-NET to Enable Dosimetry and Treatment Planning for Refractory or Relapsed Metastatic Neuroendocrine Tumors with [212Pb]Pb-VMT-α-NET
. Journal of Nuclear Medicine; 2026.
2025
Michler E, Kästner D, Pretze M, Hartmann H, Freudenberg R, Schultz MK, Bundschuh RA, Kotzerke J, Brogsitter C. [203/212Pb]Pb-VMT-α-NET As a Novel Theranostic Pair for Targeted Alpha Therapy - First Clinical Experience
. European Journal of Nuclear Medicine and Molecular Imaging; 2025, 52(11):4171-4183.
Kästner D, Hartmann H, Freudenberg R, Pretze M, Brogsitter C, Schultz MK, Kotzerke J, Michler E. Gamma Camera Imaging Characteristics of 203/212Pb as a Theragnostic Pair for Targeted Alpha Therapy: a Feasibility Study
. EJNMMI Physics; 2025;12(1):50.
2024
Sarrami N, Nelson B, Leier S, Wilson J, Chan C, Meens J, Komal T, Ailles L, Wuest M, Schultz M, Lavasanifar A, Reilly RM, Wuest F. SPECT/CT Imaging of EGFR-Positive Head and Neck Squamous Cell Carcinoma Patient-Derived Xenografts With 203Pb-PSC-Panitumumab in NRG Mice
. EJNMMI Radiopharma and Chemistry. 2024 Nov 26;9(1):79.
Bauer D, Carter LM, Atmane M, Gregorio RD, Michel A, Kaminsky S, Monette S, Li M, Schultz MK, Lewis JS. 212Pb-Pretargeted Theranostics for Pancreatic Cancer
. Journal of Nuclear Medicine; 2024, 65(1):109-116.
Graves S, Li M, Lee D, & Schultz MK. On the Use of 203Pb Imaging to Inform 212Pb Dosimetry for 203/212Pb Image-Guided Alpha-Particle Therapy for Cancer
. In: Prasad, V. (eds) Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum. Springer, Cham. 2024, pp 277–287.
Gape PMD, Schultz MK, Stasiuk GJ, Terry SYA. Towards Effective Targeted Alpha Therapy for Neuroendocrine Tumours: A Review
. Pharmaceuticals; 2024, 17(3):334.
Thakral P, Sen IB, Das SS, Schultz MK, Kumari J, Virupakshappa CB, Malik D. Lead-203 VMT-α-Neuroendocrine Tumor Scintigraphy: A Promising Theranostics Agent
. Indian Journal of Nuclear Medicine; 2024, 39(2):142-143.
Singh N, Rana N, Thakral P, Malik D, Schultz MK, Sen IB. Charting the Course of Targeted α Therapy with First-in-Human, Postadministration Image-Guided Dosimetry and Response Assessment of 212Pb-VMT-α-NET in Metastatic Neuroendocrine Tumors
. Clinical Nuclear Medicine; 2024, 49(6):546-548.
Li M, Robles-Planells C, Liu D, Graves SA, Vasquez-Martinez G, Mayoral-Andrade G, Lee D, Rastogi P, Marks BM, Sagastume EA, Weiss RM, Linn-Peirano SC, Johnson FL, Schultz MK, Zepeda-Orozco DZ. Pre-Clinical Evaluation of Biomarkers for the Early Detection of Nephrotoxicity Following Alpha-Particle Radioligand Therapy
. European Journal of Nuclear Medicine and Molecular Imaging; 2024, 51(5):1395-1408.
2023
Saini S, Bartels J, Appiah JPK, Rider JH, Baumhover N, Schultz MK, Lapi SE. Optimized Methods for the Production of High-Purity 203Pb Using Electroplated Thallium Targets
. Journal of Nuclear Medicine; 2023, 64(11):1791-1797.
Pretze M, Michler E, Runge R, Wetzig K, Tietze K, Brandt F, Schultz MK, Kotzerke J. Influence of the Molar Activity of 203/212Pb-PSC-PEG2-TOC on Somatostatin Receptor Type 2-Binding and Cell Uptake
. Pharmaceuticals (Basel); 2023, 16(11):1605.
Michler E, Kästner D, Brogsitter C, Pretze M, Hartmann H, Freudenberg R, Schultz MK, Kotzerke J. First-in-Human SPECT/CT Imaging of [212Pb]Pb-VMT-α-NET in a Patient with Metastatic Neuroendocrine Tumor
. European Journal of Nuclear Medicine; 2023, (5):1490-1492.
Lee D, Li M, Liu D, Baumhover NJ, Sagastume EA, Marks BM, Rastogi P, Pigge FC, Menda Y, Johnson FL, Schultz MK. Structural Modifications Toward Improved Lead-203/Lead-212 Peptide-Based Image-Guided Alpha-Particle Radiopharmaceutical Therapies for Neuroendocrine Tumors
. European Journal of Nuclear Medicine; 2023, 51(4):1147-1162.
Li M, Baumhover NJ, Liu D, Cagle BS, Boschetti F, Paulin G, Lee D, Dai Z, Obot ER, Marks BM, Okeil I, Sagastume EA, Gabr M, Pigge FC, Johnson FL, Schultz MK. Preclinical Evaluation of a Lead Specific Chelator (PSC) Conjugated to Radiopeptides for 203Pb and 212Pb-Based Theranostics
. Pharmaceutics, 2023, (15), 414.
Nelson BJB, Wilson J, Schultz MK, Andersson JD, Wuest F. High-Yield Cyclotron Production of 203Pb Using a Sealed 205Tl Solid Target
. Nuclear Medicine and Biology, 2023, (116-117), 108314.
Mueller D, Herrmann H, Schultz MK, Solbach C, Ettrich T, Prasad V. [203Pb]VMT-α-NET Scintigraphy of a Patient with Neuroendocrine Tumor
. Clinical Nuclear Medicine, 2023, (48), 54-55.
2022
Zhang S, Wang H, Ren S, Chen Y, Liu D, Li M, Sagastume E, Chong HS. Synthesis and Evaluation of Diaza-Crown Ether-Backboned Chelator Containing Hydroxamate Groups for Zr-89 Chelation Chemistry
. Bioorganic and Medicinal Chemistry Letters; 2022, 72:128847.
Orcutt KD, Henry KE, Habjan C, Palmer K, Heimann J, Cupido JM, Gottumukkala V, Cissell DD, Lyon M, Hussein AI, Liu D, Li M, Johnson FL, & Schultz MK. Dosimetry of [212Pb]VMT01, a MC1R-targeted Alpha Therapeutic Compound, and Effect of Free 208Tl on Tissue Absorbed Doses
. Molecules, 2022, 27(18):5831.
Schultz MK, Pouget JP, Wuest F, Nelson B, Andersson J, Cheal S et al. Radiobiology of Targeted Alpha Therapy
. In Nuclear Medicine and Molecular Imaging: Volume 1-4, 2022, 4:380-403.
2021
Kunos CA, Mankoff DA, Schultz MK, Graves SA, Pryma DA. Radiopharmaceutical Chemistry and Drug Development - What's Changed?
Seminars in Radiation Oncology, 2021, 31(1):3-11.
Li M, Liu D, Lee D, Cheng Y, Baumhover NJ, Marks BM, Sagastume EA, Ballas ZK, Johnson FL, Morris ZS, Schultz MK. Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant Melanoma
. Cancers, 2021, 13(15):3676.
2020
Li M, Sagastume EA, Lee D, McAlister D, DeGraffenreid AJ, Olewine KR, Graves SA, Copping R, Mirzadeh S, Zimmerman BE, Larsen RH, Johnson FL, and Schultz MK. Pb-203/Pb-212 Theranostic Radiopharmaceuticals for Image-Guided Radionuclide Therapy for Cancer
. Current Medicinal Chemistry, 2020, 27(1):1-29.
2019
Li M, Liu D, Lee D,Kapoor S, Gibsen-Corley KN, Quinn TP, Sagastume EA, Mott SL, Walsh SA, Avacedo MR, Johnson FL, Schultz MK. Enhancing the Efficacy of Melanocortin 1 Receptor-Targeted Radiotherapy by Pharmacologically Upregulating the Receptor in Metastatic Melanoma
. Molecular Pharmaceutics, 2019,16(9):3904-3915.
2018
Menda Y, Madsen MT, O'Dorisio TM, Sunderland J, Watkins LG, Dillon JS, Mott SL, Schultz MK, Zamba GKD, Bushnell DL, O'Dorisio MS. 90Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy
. Journal of Nuclear Medicine, 2018, 59(11):1692-1698.
Lee D, Li M, Bednarz B, Schultz MK. Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy
. Radiation Research, 2018, 190(3):236-247.
Ghai A, Singh B, Li M, Daniels TA, Coelho R, Orcutt K, Watkins GL, Norenberg JP, Cvet D, Schultz MK. Optimizing the Radiosynthesis of [68Ga]DOTA-MLN6907 Peptide Containing Three Disulfide Cyclization Bonds - A GCC Specific Chelate for Clinical Radiopharmaceuticals
. Applied Radiation and Isotopes, 2018, 140:333-341.
2017
Li M, Zhang X, Quinn TP, Lee D, Liu D, Kunkel F, Zimmerman BE, McAlister D, Olewine K, Menda Y, Mirzadeh S, Copping R, Sagastume, Johnson FL, Schultz MK. Production of High Specific Activity [203/212-Pb]DOTA-Conjugated Radiopharmaceuticals for Clinical Image-Guided Radionuclide Cancer Therapy Using an Automated Cassette-Based System
. Applied Radiation and Isotopes, 2017, 127:52-60.
May D, Nelson AN, Schultz MK. Quantitation of Lead-210 (Pb-210) Using Lead-203 (Pb-203) as a 'Massless' Yield Tracer
. Journal of Environmental Radioactivity, 2017, 171:93-98.
Stay up to date
Want to keep up-to-date on news and information?
Sign up for Email Alerts
By subscribing you agree to our Privacy Policy
.
About
Technology
Therapeutic Areas
Pipeline
Newsroom
Investor Center

© 2026 Perspective Therapeutics
. All Rights Reserved.
Investor Relations Website By VendorGroup®